Orchestration of Chemomobilization and G-CSF Administration for Successful Hematopoietic Stem Cell Collection

被引:12
|
作者
Kriegsmann, Katharina [1 ]
Schmitt, Anita [1 ]
Kriegsmann, Mark [2 ]
Bruckner, Thomas [3 ]
Anyanwu, Adamma [4 ]
Witzens-Harig, Mathias
Mueller-Tidow, Carsten [1 ]
Klein, Stefan [5 ]
Wuchter, Patrick [4 ]
机构
[1] Heidelberg Univ, Dept Med 5, Heidelberg, Germany
[2] Heidelberg Univ, Inst Pathol, Heidelberg, Germany
[3] Heidelberg Univ, Inst Med Biometry & Informat, Heidelberg, Germany
[4] Heidelberg Univ, Inst Transfus Med & Immunol, Med Fac Mannheim, German Red Cross Blood Serv Baden Wurttemberg Hes, Friedrich Ebert Str 107, D-68167 Mannheim, Germany
[5] Heidelberg Univ, Univ Med Ctr Mannheim, Med Fac Mannheim, Dept Med 3, Mannheim, Germany
关键词
G-CSF; Stem cell mobilization; PBSC; Chemomobilization; NON-HODGKINS-LYMPHOMA; PLUS G-CSF; PRIMARY SYSTEMIC AMYLOIDOSIS; DIAGNOSED MULTIPLE-MYELOMA; LOW-DOSE CYCLOPHOSPHAMIDE; SINGLE-CENTER EXPERIENCE; AUTOLOGOUS TRANSPLANTATION; MODIFIED CISPLATIN; MARROW TRANSPLANTATION; SALVAGE THERAPY;
D O I
10.1016/j.bbmt.2018.01.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Successful collection of peripheral blood stem cells (PBSCs) depends on the optimal orchestration of mobilization chemotherapy, granulocyte colony stimulating factor (G-CSF) application, and CD34(+) cell number assessment in the peripheral blood (PB). However, determining the optimal timing in accordance to the applied chemomobilization regimen can be challenging. Although most centers apply their own local timing schedules, a reliable timetable including the currently most often used mobilization regimens is lacking. We present a comprehensive analysis of the timing modalities for 11 of the most commonly used chemomobilization regimens. A retrospective analysis was performed on the clinical and PBSC collection parameters (including duration of G-CSF application, time point of CD34(+) assessment, PB CD34+ cell count, number of leukapheresis [LP] sessions, processed blood volume, and CD34(+) collection results) of 91 representatively selected patients who had undergone stem cell mobilization at 2 collection centers. Six to 10 patients were analyzed per regimen with a variety of diagnoses, including multiple myeloma, malignant lymphoma, and sarcoma. No collection failures (<2 x 10(6) CD34(+) cells/kg body weight) were observed. All analyzed patients successfully reached their individual collection goal in adherence to the given schedule of chemotherapy, application of G-CSF, measurement of CD34(+) cells, and subsequent LP. The presented data on the timing of chemomobilization, G-CSF application, and stem cell collection may be helpful in clinical decision making and contribute to a more transparent and predictable treatment process. (C) 2018 American Society for Blood and Marrow Transplantation.
引用
收藏
页码:1281 / 1288
页数:8
相关论文
共 50 条
  • [1] Optimal timing of G-CSF administration for effective autologous stem cell collection
    Kim, J. E.
    Yoo, C.
    Kim, S.
    Lee, D. H.
    Kim, S-W
    Lee, J-S
    Suh, C.
    BONE MARROW TRANSPLANTATION, 2011, 46 (06) : 806 - 812
  • [2] Chemomobilization with high-dose etoposide and G-CSF results in effective and safe stem cell collection in heavily pretreated lymphoma patients: report from a single institution study and review
    Ozkan, Hasan Atilla
    Bal, Cengiz
    Gulbas, Zafer
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 92 (05) : 390 - 397
  • [3] Optimal timing of G-CSF administration for effective autologous stem cell collection
    J E Kim
    C Yoo
    S Kim
    D H Lee
    S-W Kim
    J-S Lee
    C Suh
    Bone Marrow Transplantation, 2011, 46 : 806 - 812
  • [4] Optimal use of G-CSF administration after hematopoietic SCT
    Trivedi, M.
    Martinez, S.
    Corringham, S.
    Medley, K.
    Ball, E. D.
    BONE MARROW TRANSPLANTATION, 2009, 43 (12) : 895 - 908
  • [5] G-CSF Only Versus Chemotherapy and G-CSF Peripheral Blood Stem Cell Mobilization for Autologous Hematopoietic Stem Cell Transplant-Assessing a Change in Regime due to the COVID-19 Pandemic
    Wolf, Julia S.
    Seymour, Frances
    Parrish, Christopher
    Chandler, Thea
    Holt, Matthew
    Griffin, James
    Karakantza, Marina
    JOURNAL OF CLINICAL APHERESIS, 2025, 40 (02)
  • [6] Optimal use of G-CSF administration after hematopoietic SCT
    M Trivedi
    S Martinez
    S Corringham
    K Medley
    E D Ball
    Bone Marrow Transplantation, 2009, 43 : 895 - 908
  • [7] Can G-CSF Cause Leukemia in Hematopoietic Stem Cell Donors?
    Avalos, Belinda R.
    Lazaryan, Aleksandr
    Copelan, Edward A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (12) : 1739 - 1746
  • [8] Successful of autologous hematopoietic stem cell mobilization with plerixafor combined with G-CSF in pediatric neuroblastoma patients, a single center experience
    Jafari, Leila
    Hematyar, Fatemeh
    Karamlou, Yalda
    Alipour, Nadia
    Mohseni, Rashin
    Jafari, Fahimeh
    Nikfetrat, Zeynab
    Behfar, Maryam
    Hamidieh, Amir Ali
    TRANSFUSION AND APHERESIS SCIENCE, 2025, 64 (01)
  • [9] AUTOLOGOUS HEMATOPOIETIC STEM CELL MOBILIZATION USING CHEMOTHERAPY PLUS G-CSF VS. G-CSF ONLY: COMPARISON OF SAFETY, EFFICACY AND PRODUCT QUALITY
    Dill, V.
    Bluem, P.
    Lindemann, A.
    Manske, K.
    Hoegner, M.
    Bassermann, F.
    Hildebrandt, M.
    CYTOTHERAPY, 2024, 26 (06) : S95 - S95
  • [10] A clinical comparison of the efficacy and safety of biosimilar G-CSF and originator G-CSF in haematopoietic stem cell mobilization
    Joanna Manko
    Adam Walter-Croneck
    Dariusz Jawniak
    Norbert Grzasko
    Magdalena Gorska-Kosicka
    Maria Cioch
    Anna Dmoszynska
    Pharmacological Reports, 2014, 66 : 239 - 242